While it may have been a chaotic year for the US Food and Drug Administration (FDA) due to layoffs, leadership changes and ...

Japanese biotech Nxera Pharma (TSE: 4565) has revealed that Germany’s Boehringer Ingelheim opted not to exercise its ...

The US president has signed an Executive Order directing federal agencies to move more quickly toward rescheduling marijuana ...

Danish clinical-stage techbio Evaxion today revealed it has been informed that MSD (tradename of Merck & Co outside the USA ...

Iceland-based biosimilars developer Alvotech and a US affiliate of Israel’s Teva Pharmaceutical Industries, today announced ...

US radioisotope producer Niowave has expanded its supply agreement with British pharma AstraZeneca (LSE: AZN) to a 10-year ...

Syremis Therapeutics, a Tel Aviv, Israel, and Boston, USA-based clinical-stage biopharma developing novel medicines to make a ...

Orum Therapeutics, a Korea-listed biotech developing degrader-antibody conjugates (DACs), has secured 145 billion South ...

The USA’s Coalition for Epidemic Preparedness Innovations (CEPI) will invest up to $54.3 million to support a pivotal Phase III clinical trial that aims to help advance Moderna’s investigational ...

Shares of Amicus Therapeutics shot up 30% to $10.89 in pre-market activity today, on the news of a takeover offer from fellow USA-based BioMarin.

US precision allosteric therapeutics company Atavistik Bio has raised a $120 million Series B financing.

South Korean biosimilars specialist Celltrion said the European medicines regulator has adopted a positive opinion for an autoinjector version of SteQeyma, its biosimilar to Stelara (ustekinumab).